Tempus Announces New Subscription Service for Pharma, Biotech and Academic Researchers



Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announced today that it is providing its de-identified datasets via a data subscription, enabling researchers to leverage unique, longitudinally-updated clinical and molecular data at scale, which will help accelerate therapeutic discovery, development and commercialization.

Tempus currently collaborates with 80% of the world’s leading oncology companies by exploring the genotypic and phenotypic characteristics of cancer patient populations.  Tempus aggregates this de-identified data across a wide network of community oncologists, academic medical centers and NCI-designated cancer centers, touching roughly 4,000 oncologists in the US.

By bundling the de-identified data by subtype or molecular biomarkers, Tempus is building real world evidentiary data sets that tie outcome and response to a wide variety of genomic and transcriptomic biomarkers at scale.

“Our partners are looking for a comprehensive platform that can enable them to better understand the clinical context and molecular profile of patients, so that they can accelerate the discovery, development, and commercialization of more targeted and effective drugs,” said Ryan Fukushima, Chief Operating Officer at Tempus. “Tempus’ real-world evidence offerings enable our partners a unique perspective to unlock insights as therapeutics becomes more and more targeted. With our platform, we are delivering datasets at a size and depth that were historically not feasible, enabling data-driven decisions as part of the drug development and commercialization process.”

Tempus’ current industry partnerships support a broad array of use cases, including sequencing for clinical trials, licensing clinical and molecular data for R&D initiatives, enriching translational research by identifying areas of unmet medical need, clinical trial design and recruitment, and predicting response or resistance to on-market targeted therapies.

Building larger, comprehensive datasets and organizing it in one place are critical initial steps to leverage the power of big data. The Tempus platform incorporates a combination of de-identified data types at a patient-level, including molecular sequencing data, structured clinical data, and structured imaging data in a common data format across academic and community-based hospitals. These datasets, in turn, power a variety of clinical and research applications and use cases, enabling research teams to harness the power of artificial intelligence and deliver data-driven solutions to healthcare.

About Tempus

Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful, in an effort to bring the power of artificial intelligence to healthcare.  We enable physicians to make real time, data driven decisions and deliver personalized care for patients through our interactive analytical and machine learning platform. Our goal is for each patient to benefit from the treatment of others who came before by providing the health care industry with tools that learn as we gather more data. For more information, visit tempus.com.